Intestinal inflammation is controlled by various immunomodulating cells, interacting by molecular mediators. Neuropeptides, released by enteric nerve cells and neuroendocrine mucosa cells, are able to affect several aspects of the general and intestinal immune system, with both pro- as well as anti-inflammatory activities. In inflammatory bowel disease (IBD) there is both morphological as well as experimental evidence for involvement of neuropeptides in the pathogenesis. Somatostatin is the main inhibitory peptide in inflammatory processes, and its possible role in IBD is discussed.

Key words: Inflammatory bowel disease, Neuropeptide, Somatostatin, Gastrointestinal immune system

Introduction

Ulcerative colitis and Crohn’s disease are both characterized by chronic, relapsing intestinal inflammation. The aetiology of both forms of inflammatory bowel disease (IBD) is still unknown, despite intensive research in two main areas—abnormal regulation of the local immune response and exogenous factors, including infectious agents. The gastrointestinal immune system protects the organism against toxins, microorganisms and dietary antigens within the gut lumen. It is generally assumed that luminal stimuli presented to intestinal mucosa activate intra-epithelial immunocytes resulting in release of mediators of inflammation. In IBD an inflammatory cascade is initiated and, due to insufficient or inappropriate immune reactions, intestinal damage results. The reasons for inappropriate immune activation are unknown. Central roles are currently ascribed in this process to activated intestinal macrophages and T-lymphocytes in combination with an imbalance between pro- and contra-inflammatory T-cells. Treatment of IBD is aimed at reducing the production or action of mediators of inflammation.

Delicate interactions of intestinal mucosal epithelium, smooth muscle cells, gut wall blood vessel endothelium, immunocytes and enteric nerve cells contribute to and regulate intestinal inflammatory changes. These processes are mediated by various chemical messengers, most of which are produced by lymphocytes, granulocytes and macrophages. Recent studies on aetiopathogenesis and treatment in IBD have concentrated on these immunocyte products which include cytokines, eicosanoids and adhesion molecules. The contribution of other elements of the gastrointestinal immunological defence system to chronic intestinal inflammation is less well known. A potentially interesting area is the immunoregulatory role of enteric nerves and neuroendocrine cells. Neuropeptides, like substance P (SP), somatostatin (SMS), vasoactive intestinal peptide (VIP) and calcitonin gene related peptide (CGRP), are the molecular mediators of neuroregulation of the intestinal immune system, providing for interactions between nervous system and immunocytes. SMS is a key inhibiting factor of many biological processes. In this review the role of SMS as neuroimmune modulator in IBD will be highlighted, together with its possible future use in the treatment of IBD.

Neuroinflammation, Neuropeptides and Intestinal Inflammation

The concept of neuroimmune interaction is in part derived from older clinical observation that inflammatory processes are influenced by emotional or physical stress. The immune system is subject to central nervous control and Pavlovian responses. Although IBD patients do not have more emotional difficulties or psychosocial stress compared with a normal population, disease activity and response to therapy are certainly influenced by the state of mental well-
being. The interaction between nervous system and the intestinal immune system is probably mediated by neuropeptides derived from enteric nerves and neuroendocrine cells.

Membrane-bound neuropeptide receptors are found on several immune cells, including T-lymphocytes and monocytes. Various neuropeptides affect intestinal lymphocyte function and several cells of the intestinal immune system also produce neuropeptides, suggesting a local immunoregulatory task. Migration of immune cells into the intestinal mucosa is affected by neuropeptides.

In addition there are several morphological arguments that suggest neuropeptide involvement in intestinal mucosal immunity. Intestinal mucosa contains SP, VIP and SMS immunoreactive nerve fibres and co-localization is common. Neuropeptides show a specific distribution along the gut. Transmural distribution can be different for different neuropeptides.

The reported studies of neuropeptide immunomodulation in the intestine need to be interpreted with some caution. Receptor binding studies often show unexpected concentration relationships and depend strongly on local conditions. There are several morphological arguments that suggest neuropeptide involvement in intestinal mucosal immunity. Intestinal mucosa contains SP, VIP and SMS immunoreactive nerve fibres and co-localization is common. Neuropeptides show a specific distribution along the gut. Transmural distribution can be different for different neuropeptides.

The interaction between nervous system and the intestinal immune system is probably mediated by neuropeptides derived from enteric nerves and neuroendocrine cells. In mucosal lymphocytes from resected human colon segments, 3H-thymidine uptake, DNA synthesis as measured by 3H-thymidine uptake, is inhibited by low concentrations of SMS, VIP, SP and bombesin. This inhibition might be principally achieved by T-cell suppression, as it is observed in lymphocytes that are stimulated by concanavalin A. The maximum inhibitory effects are obtained after 4 days of neuropeptide incubation. VIP and SMS inhibit lymphocytic proliferation in a dose-dependent fashion. The inhibitory effects of VIP and SMS on these lymphocytes are mediated by specific receptors, not by cytotoxicity. VIP has both pro- and anti-inflammatory effects on intestinal T-cells and macrophages, inducing IL-5 release and inhibiting macrophage adherence. T-cell cAMP increases on stimulation by VIP, but proliferation is inhibited. However, reactivity of granuloma B-cells and macrophages is not affected.

Conflict results emerge from studies in IBD patients. SP content of inflamed colon is increased, but there is a substantial overlap with normal SP content. SP receptor upgrading is observed in inflamed areas of IBD colon. For VIP the observations are even more confusing. Whereas VIP concentration in plasma of patients with active IBD is increased, colon VIP content is reported to be either decreased or increased. There is no clear relation between VIP content and disease activity.

Somatostatin

SMS was first extracted from ovine hypothalamus as an inhibitor of growth hormone secretion. SMS is a peptide hormone. There are two biologically active forms, consisting of 14 or 28 amino acids respectively. Most of the total body SMS content is stored in the digestive tract. About 75% is localized in gut and pancreas. In stomach and pancreas SMS-14 prevails, and in the gut SMS-28. SMS containing cells are found in enteric mucosa, submucosa and neural tissue. More than 90% of gut SMS content is localized in the endocrine cells of the mucosa, less than 10% in enteric nerves of the muscular layer.

Five types of SMS receptors have been discovered, each with specific binding characteristics for SMS subtypes and different SMS analogues. SMS receptors are found in upper and lower parts of the normal digestive tract. SMS is an inhibitor of several key functions in
the body. SMS inhibits acid secretion, intestinal fluid absorption, intestinal and pancreas secretion. SMS has effects on splanchnic blood flow and gastric and intestinal motility. SMS exerts its inhibitory effects by diminishing intracellular cAMP through G-protein activation. In addition, SMS impedes cellular influx of calcium. This impediment results from a direct effect on calcium channels and from increase of potassium conductance with subsequent cellular hyperpolarization. Circulating native SMS has a short half-life time. Long-acting analogues like the decapeptide octreotide have been developed and SMS analogues have been used to treat intractable diarrhoea, bleeding from oesophageal varices in portal hypertension, dumping syndrome and gastrointestinal fistulae. Radioactive labelled SMS analogues serve as diagnostic tools in visualization of gastrointestinal neuroendocrine tumours.

**Immunomodulatory Effects of Somatostatin**

Studies on the immunomodulatory effects of SMS show several effects on T- and B-lymphocytes and macrophages. SMS receptors exist in spleen, liver, thymus and gastrointestinal lymphoid tissue, as well as on various immune cells. Immunomodulating actions of SMS were discovered as a result of its antagonizing effects of proliferation of rat lymphocytes, stimulated by hypothalamic extracts. SMS inhibits responsiveness, immunoglobulin synthesis and proliferation of lymphocytes and granulocytes. It reduces TNF release and cellular toxicity of stimulated rat peritoneal macrophages. Inhibitory effects depend on local SMS concentration. Several in vitro studies show inhibition of proliferation of lymphoid cells at low SMS concentrations and stimulation at high levels. In an experimental model of intestinal inflammation with Schistosoma mansoni, SMS as well as its analogue octreotide decrease T-cell interferon production significantly.

Some studies report immunostimulating effects by SMS. T-cell proliferation is seen, also at low SMS concentrations. In rat peritoneal macrophages SMS stimulates cytotoxic reactivity, when given in low concentrations. T-cell activation in a hybridoma T lymphocyte cell line, measured by IL-2 release, is stimulated by SMS in a dose-dependent way. However, IL-2 receptor expression is inhibited by SMS in human intestinal lymphocytes.

SMS controls inflammatory processes in vivo experimental models. A reduction of inflammatory infiltrate and a diminished TNFα production occurs when SMS analogues are applied to animals in which carrageen-induced skin inflammation is established. In this experiment intense SMS immunostaining was seen on leukocytes at peri-inflammation sites. SMS reduces inflammation in experimental arthritis and ileal obstruction. Similar beneficial effects on intestinal and colonic inflammation emerge from clinical observations in Crohn’s disease and gold-induced enteritis. SMS is able to reduce SP mediated inflammation induced by intestinal infection with Trichinella spiralis and SP enhanced neutrophil chemotaxis.

**Somatostatin in IBD**

No systematic in vivo or in vitro studies on effects of SMS in IBD are available at present. Support for SMS induced immunomodulation in IBD is indirect and derived from morphological and biochemical analyses of intestinal and blood specimens from IBD patients. From several studies a correlation between SMS activity and presence and intestinal inflammation emerges.

When measured in serum total body SMS release shows a circadian rhythm. In active ulcerative colitis a higher 24-hour amplitude, higher average serum levels and a longer meal-stimulated peak level are observed. As the serum concentration is only a faint mirror of the mucosal events, the impact of increased secretion of SMS is obscure. Some response patterns are seen in patients with duodenal ulcer or irritable bowel syndrome.

SMS containing cells and submucosal ganglion cells in surgical specimen from IBD patients can be visualized by immunohistochemical staining and quantified by counting the SMS containing cells per cm. Mucosal SMS content can be assessed by radioimmunoassay of homogenised biopsy specimen. In normal colon mucosa, SMS containing endocrine cells show the highest density in the distal parts. In active IBD this distinct difference disappears. Studies prior to the discovery of SMS showed a decrease of neuroendocrine enterochromaffin cells in diseased rectum of ulcerative colitis patients. In ulcerative colitis there is an actual decrease in SMS containing cells, especially in the distal part of the colon. Although these changes may be secondary to inflammatory damage to mucosal SMS containing cells, this is refuted by the fact that other mucosal neuropeptides like SP show increased levels in these cases. SMS containing submucosal ganglion cells are evenly distributed along the colon in normals and IBD patients, but the number of these cells is
decreased in IBD. In colon epithelial cell cultures from patients with active ulcerative colitis, decreased SM S generation is observed. This loss of SM S production correlates with disease activity.

In Crohn’s disease the loss of SM S containing colonic cells is less evident. A tendency towards decrease of SM S positive cells with increasing disease activity has been reported. No difference of SM S content is seen in mucosa or normal ileum and terminal ileitis. Mucosal biopsies from inflamed jejunum in Crohn’s disease show normal levels of SM S, but soluable SM S is increased. This may reflect instability of SM S storage granules due to inflammation.

Several arguments for SM S involvement in mucosal inflammation emerge from scintigraphic studies. An increased density of SM S receptors is found in areas of granulomatous inflammation like tuberculosis, sarcoidosis and Wegener’s granulomatous. From SM S receptor measurements in granulomas of murine intestinal Schistosoma mansoni infestation emerge the same results.

High-affinity SM S receptors are found in normal jejunum, ileum and colon. Apart from presence in colon mucosa and nerve plexus, SM S receptors are found in the germinal centres of colonic lymph follicles. SM S receptors are seen in gut-associated lymphatic tissue, like palatine tonsils, Peyer’s patches, vermicular appendix and isolated lymphatic follicles in the colon and SM S is isolated from nervous tissue in Peyer’s patches. The precise function of SM S in this gut-associated lymphoid tissue has not yet been settled. High receptor density is seen in the luminal parts of secondary lymph follicles, but they are absent from the corona of B-lymphoid cells. Lymphoid aggregates without a germinal centre do not show receptor activity. Interaction of SM S and lymphocytes from these germinal centres is reasonable. As these receptors have high affinity for SM S, a specific immunomodulatory role of SM S is anticipated. Other indications for a direct influence of SM S on intestinal immunocytes can be derived from electron microscopic studies of the gut wall. SM S containing enteric nerve fibres are present in a very high density near intestinal lymph follicles, coming close to follicular lymphocytes.

Inhibitory effects of SM S on vascular cell proliferation have been described. Expression of high affinity SM S receptors is seen in intramural veins of inflamed intestinal mucosa in IBD or peri-inflammatory veins in rheumatoid arthritis. No difference is seen in SM S receptor content of normal and inflamed tissue in mucosa, nerve plexus or lymphatic follicles. Precise cellular localization of the SM S receptors is not possible from autoradiography, due to insufficient resolution of this visual technique. Histologically these receptor positive veins are normal, but the surrounding tissue often is infiltrated by leukocytes and receptor positivity is correlated with IBD activity. However, expression of SM S receptors in vessel walls could be a nonspecific response to inflammation as this phenomenon is also seen in peritumoral tissues in resected SM S receptor negative colon adenocarcinoma and other malignancies.

In animal experimental models of inflammatory bowel disease there are several suggestions of a role of SM S in the inflammatory mucosal responses. In murine experimental colitis SM S prevents mucosal damage effectively, especially when given before the introduction of the toxin. Parallel to decrease of mucosal lesions a decrease of inflammatory mediators such as leukotriene B4 and platelet activating factor is seen.

Interleukin-2 receptor expression and DNA synthesis in intestinal lamina propria lymphocytes (LPL) is reduced by SM S. Proliferation of Peyer’s patch derived lymphocytes is inhibited by SM S. Inhibitory effects of SM S on lymphocytic proliferation are more pronounced in intestinal derived T-cells than in splenic lymphocytes. Affinity of lamina propria lymphocytes for SM S-binding was found to be 1000 times higher than peripheral blood lymphocytes in one study.

However, conflicting results emerge from a study in which effects on human peripheral blood lymphocytes and intestinal LPL were compared. The effects of SM S on intestinal LPL were minimal. Although both lymphoid cells expressed high affinity SM S receptors, intestinal lymphoid proliferation was poorly inhibited by SM S. Immunoglobulin synthesis was affected in a dose-related way in both peripheral and intestinal lymphocytes. The fact that these results run counter to earlier reported data, may be due to species differences and the lack of SM S receptor subtyping.

Intestinal granulomas induced by Schistosoma mansoni are smaller in the presence of SM S. Their output of interferon γ and immunoglobulin is diminished by SM S. As these same granulomas are also capable of producing SM S, this suggests a local immunoregulatory role for SM S. This is supported by the interesting observation that intra-epithelial lymphoid cells can stimulate isolated intestinal epithelium to produce SM S.
Conclusion
From morphological studies it is clear that neuropeptides are probably involved in the control of the intestinal immune system. Immune stimulatory and inhibitory effects emerge from various in vitro studies and from sparse in vivo experiments. SMS has been shown to inhibit immunological processes at various sites following different stimuli. As SMS receptors show a high density in the gastrointestinal associated lymphoid tissue and in inflammatory granulomas in murine Schistosoma mansoni infestation, it seems likely that SMS and its receptors play a role in immunological events of the digestive tract. Mucosal SMS content is reduced in active IBD. The beneficial effects of SMS and SMS analogues on experimental inflammation of skin, joints and intestine and the few reports on open studies in patients with IBD suggest that SMS and SMS analogues could possibly be beneficial in IBD and should stimulate further clinical studies.

References


Goetzl EJ, Payan DG. Inhibition by somatostatin of the release of mastocytes from human peritoneal macrophages by a mechanism that involves cAMP. J Adhes Commun 1993; 11: 213–221.


Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Gastroenterology 1994; 107: 624–634.


Belfer G. Octreotide acetate (Sandostatin) to control the symptoms of Crohn's disease. Lancet 1993; 342: 179.

Benes G. Octreotide acetate (Sandostatin) to control the symptoms of Crohn's disease. Am J Gastroenterol 1993; 88: 1603.


Submit your manuscripts at http://www.hindawi.com